McKesson EPS up 19.6% Drives 144% Return, Shifts Focus to Oncology
McKesson’s net income grew 14.4% annually over three years while EPS rose 19.6%, generating a 144% total share return and $10 billion in yearly operational cash flow. With $838 million capex, 2.7% net shareholder yield and 18% EPS growth outlook, McKesson pivots to high-margin oncology to offset GLP-1 margin pressure.
1. Strong Earnings Growth and Returns
McKesson recorded a 14.4% average annual net income increase and 19.6% EPS growth over three years, fueling a 144% total stock return. This performance reflects both fundamental profit gains and the compounding impact of systematic share repurchases.
2. Robust Cash Generation and Shareholder Returns
The company directs billions of pharmaceutical units, producing $10 billion in annual operational cash flow. With disciplined $838 million capex, McKesson sustains a 2.7% net shareholder yield through dividends and buybacks, and has raised its full-year EPS growth outlook to 18%.
3. Financial Stability Metrics
Interest coverage stands at 25.2x, indicating strong capacity to service debt, while a 3.5 payout funding ratio shows cash flow covers shareholder returns multiple times over. This financial flexibility underpins investments in higher-margin segments.
4. Strategic Pivot to Oncology and Risks
High-margin oncology grew 57%, but the rise of lower-margin GLP-1 drugs is compressing overall margins. Investors will watch the May 7 Q4 earnings call to gauge whether oncology expansion can offset GLP-1 pressure and sustain profitability.